# FLEX breast cancer gene-expression registry

Source: https://onco.cc/trials/nct03053193/  
OnCo record `nct03053193` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FLEX links breast tumor gene-expression tests with clinical outcomes. It is a registry for studying new patterns in the data, rather than assigning a new treatment.

## Summary

FLEX links breast tumor gene-expression tests with clinical outcomes. It is a registry for studying new patterns in the data, rather than assigning a new treatment.

Observational study registered as NCT03053193, sponsored by Agendia. Registry enrollment is 30,000 participants (estimated). Registry status checked October 10, 2026: recruiting. UCSF lists this study as open to eligible people; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-10
- Also known as: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- Tags: ucsf-breast-coverage; observational
- Registry id: NCT03053193
- Phase: observational
- Setting: Stage I to III breast cancer with MammaPrint and BluePrint testing
- Sponsor: Agendia

## Sources

- ClinicalTrials.gov NCT03053193: https://clinicaltrials.gov/study/NCT03053193
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT03053193

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct03053193.json